Summary by Futu AI
On July 30, 2024, 180 Life Sciences Corp. announced positive topline results from a clinical pharmacology study evaluating a new solid formulation of cannabidiol (CBD) with enhanced oral uptake. The study, conducted in collaboration with Prof. Avi Domb of the Hebrew University and Prof. Elyad Davidson of Hadassah Hospital, compared the pharmacokinetic profile of two solid CBD formulations against Epidiolex, an FDA-approved drug for epilepsy. Twelve volunteers participated in a crossover randomized trial, revealing that one of the solid forms was absorbed faster and reached higher maximal levels than Epidiolex, while both solid forms were well tolerated. The company believes that the solid formulation could advance the testing of CBD in other indications, such as pain and PTSD, due to its potential benefits and more desirable pill format. The full study results are pending and are expected to be submitted for scientific publication at a later date. 180 Life Sciences Corp. does not anticipate the trial's outcome to impact its financial results for the year ended December 31, 2024.